CD20-directed Cytolytic Antibody
- Name
- CD20-directed Cytolytic Antibody
- Accession Number
- DBCAT003269
- Description
Not Available
- Drugs
Drug Drug Description Rituximab A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Ofatumumab An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. Obinutuzumab An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. Ocrelizumab A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. Ublituximab A low-fucose CD20-targeted monoclonal antibody used in the treatment of relapsing forms of multiple sclerosis. - Drugs & Drug Targets